Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K.

J Bone Miner Res. 2003 Mar;18(3):482-92.

PMID:
12619933
[PubMed - indexed for MEDLINE]
2.

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI.

Int J Cancer. 2007 Apr 15;120(8):1657-63.

PMID:
17230522
[PubMed - indexed for MEDLINE]
3.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

PMID:
17495322
[PubMed - indexed for MEDLINE]
Free Article
4.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

PMID:
19016584
[PubMed - indexed for MEDLINE]
5.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K.

Blood. 2001 Dec 15;98(13):3534-40.

PMID:
11739154
[PubMed - indexed for MEDLINE]
Free Article
6.

Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.

Libouban H, Moreau MF, Baslé MF, Bataille R, Chappard D.

Bone. 2003 Sep;33(3):283-92.

PMID:
13678768
[PubMed - indexed for MEDLINE]
7.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.

J Natl Cancer Inst. 2007 Feb 21;99(4):322-30.

PMID:
17312309
[PubMed - indexed for MEDLINE]
Free Article
8.

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K.

Cancer. 2003 Feb 1;97(3 Suppl):818-24.

PMID:
12548581
[PubMed - indexed for MEDLINE]
Free Article
9.

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.

Cancer Res. 2007 Jan 1;67(1):202-8.

PMID:
17210700
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

PMID:
17546599
[PubMed - indexed for MEDLINE]
11.

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

Lawson MA, Coulton L, Ebetino FH, Vanderkerken K, Croucher PI.

Biochem Biophys Res Commun. 2008 Dec 12;377(2):453-7. doi: 10.1016/j.bbrc.2008.09.157. Epub 2008 Oct 16.

PMID:
18929536
[PubMed - indexed for MEDLINE]
12.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

PMID:
19531653
[PubMed - indexed for MEDLINE]
Free Article
13.

The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA.

Cancer Res. 2007 Oct 1;67(19):9346-55.

PMID:
17909043
[PubMed - indexed for MEDLINE]
Free Article
14.

Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.

Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.

Cancer Biol Ther. 2009 Jun;8(12):1109-16.

PMID:
19652526
[PubMed - indexed for MEDLINE]
Free Article
15.

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR.

Blood. 2008 Mar 1;111(5):2833-42. Epub 2007 Dec 19.

PMID:
18094333
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR.

Blood. 1999 Mar 1;93(5):1697-706.

PMID:
10029599
[PubMed - indexed for MEDLINE]
Free Article
17.

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K.

Am J Pathol. 2004 Sep;165(3):869-78.

PMID:
15331411
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The 5T2MM murine model of multiple myeloma: maintenance and analysis.

Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, Croucher P, Van Camp B.

Methods Mol Med. 2005;113:191-205.

PMID:
15968104
[PubMed - indexed for MEDLINE]
19.

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.

Mundy GR, Yoneda T, Hiraga T.

Semin Oncol. 2001 Apr;28(2 Suppl 6):35-44. Review.

PMID:
11346863
[PubMed - indexed for MEDLINE]
20.

Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.

Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E.

Bone. 2008 May;42(5):950-9. doi: 10.1016/j.bone.2008.01.010. Epub 2008 Feb 8.

PMID:
18337202
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk